Updates are available Correction dated 2021-09-01
Click to view Correction: https://doi.org/10.1038/s41573-021-00300-7
-
Authors
Vanhaesebroeck, Bart http://orcid.org/0000-0002-7074-3673
Perry, Matthew W. D. http://orcid.org/0000-0002-9799-0746
Brown, Jennifer R. http://orcid.org/0000-0003-2040-4961
André, Fabrice http://orcid.org/0000-0001-5795-8357
Okkenhaug, Klaus http://orcid.org/0000-0002-9432-4051
- License Information
-
More Information
Article History
Accepted: 8 April 2021
First Online: 14 June 2021
Change Date: 1 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41573-021-00300-7
Competing interests
: B.V. is a consultant for iOnctura (Geneva, Switzerland), Venthera (Palo Alto, USA), Olema Pharmaceuticals (San Francisco, USA), Pharming (Leiden, Netherlands) and has received speaker fees from Gilead (Foster City, USA). M.W.D.P. is an employee and shareholder in AstraZeneca. J.R.B. has served as a consultant for AbbVie, Acerta, AstraZeneca, Beigene, Catapult, Dynamo Therapeutics, Genentech/Roche, Gilead, Juno/Celgene, Kite, Loxo, MEI Pharma, Novartis, Octapharma, Pfizer, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; received honoraria from Janssen and Teva; received research funding from Gilead, Loxo, Sun and Verastem; and served on data safety monitoring committees for Morphosys and Invectys. F.A. received grants from AstraZeneca, Novartis, Pfizer, Eli Lilly, Daiichi Sankyo, Roche and served as consultant/speaker with fees donated to Institute Gustave Roussy, Paris, from AstraZeneca, Novartis, Pfizer, Lilly, Daiichi Sankyo, Roche and Sanofi. F.A. is a founder of Pegacsy. K.O. receives research funding from GlaxoSmithKline (Stevenage, UK) and has received consultancy and speaker fees from Gilead (Foster City, USA) and Karus Therapeutics (Oxford, UK). The other authors declare no competing interests.
